Why breathing is such an issue with Congenital Myotonic Dystrophy

Breathing is a huge and life threatening issue in myotonic dystrophy. An article recently shed some light on the reasons for this. Because of ethical issues its difficult to do live tests on humans. However, our fine researchers have created mice that have the congenital form of myotonic dystrophy. Through detailed analysis of the mice and there breathing they have isolated the issue to the neuropathology of several body systems. That means its not only the muscle issues but there are some nerve conduction issues involved as well. This information will help the drug companies as they design drugs to help not only the muscle issues but the nerves that serve to coordinate the breathing mechanisms. As a drug is introduced testing it on these mice would see if it will help the respiratory function.


Results from the Study
Because it is not feasible to take biopsies of the nervous system from
patients with DM1 for histological examinations, animal models are
indispensable for the study of the mechanisms underlying respiratory
failure in this disease. In this study, the authors test the respiratory function
and analyze the structures involved in respiratory function in DMSXL
transgenic mice, an established animal model for congenital DM1 (the severest
form of the disease, which develops at birth) that carries a very long CTG
repeat in the DMPK gene. Statistical analysis of breathing function
measurements shows that DMSXL mice have impaired respiratory function.
Histological and morphometric analyses reveal pathological changes in the
diaphragmatic neuromuscular junctions and muscle fibers of DMSXL mice and
a significant decrease in the number of unmyelinated phrenic afferents. By
contrast, DMSXL mice exhibit no significant neuronopathy in either cervical
phrenic motor neurons or brainstem respiratory neurons.
Implications and future directions
By shedding new light on the cellular mechanisms of respiratory failure in
DM1, these findings improve understanding of the main cause of death in
congenital DM1. The denervation and the pathological changes of the
diaphragmatic neuromuscular junctions observed in DMSXL mice suggest that
a breakdown in communication between the diaphragmatic muscle fibers and
the nerve endings might be the main cause of respiratory failure; the loss of
phrenic unmyelinated afferents suggests that altered regulation of breathing is
also involved. As well as contributing towards the understanding of respiratory
failure in DM1, these findings suggest that the evaluation of respiratory
parameters in DMSXL mice by non-invasive pressure plethysmography could
be used to evaluate the effect of potential therapies. Moreover, future analyses
of gene expression in DMSXL mice might contribute to our understanding of
the molecular mechanisms involved in respiratory impairment.

Identification-of-mechanisms-Respiratory-Failure-in-Myotoic-dystrophy

Print Friendly, PDF & Email

What causes the Congenital Form of Myotonic Dystrophy

This has always been a puzzle. Most cases of the congenital form of myotonic dystrophy come from the mother having myotonic dystrophy. This recent information has helped with our understanding of this separate disease.

DNA-Methylation-and-Congenital-Myotonic-Dystrophy

Print Friendly, PDF & Email

Social Connections in Myotonic Dystrophy – Keeping Active in Community

Print Friendly, PDF & Email

Lecture on consensus based care for patients with myotonic dystrophy

On May 10th 2019 at the American Academy for Neurology a talk on consensus based care for Myotonic Dystrophy Type 1 will b given at 10am. Dr, Johnson has considerable experience with this disease.

Nicholas E. Johnson, MD, FAAN, is an assistant professor of neurology, pediatrics, and pathology at the University of Utah with a focus in inherited neuromuscular disorders. He received his undergraduate degree in molecular and cellular biology and psychology at the University of Arizona. He then obtained his medical degree at the University of Arizona. He completed his neurology residency and combined fellowship in neuromuscular medicine and experimental therapeutics at the University of Rochester.

His laboratory is focused on identifying the pathogenesis of myotonic dystrophy and facioscapulohumeral muscular dystrophy and identifying appropriate clinical endpoints for these conditions. Johnson conducts therapeutic trials in many other inherited nerve and muscle disorders. He also serves as deputy editor of Neurology® Genetics.

Johnson serves as chair of the Government Relations Committee for the American Academy of Neurology. He is also a member of the American Academy of Neurology’s delegation to the American Medical Association. In these roles, Johnson advocates for improving the practice of neurology for neurologists and their patients.

Here is a link to the information on the talk http://tools.aan.com/annualmeeting/search/index.cfm?fuseaction=home.detail&id=7616&keyword=&81,81,81,81,81,81,81,81,81,81,81,81,81&type=all.

Print Friendly, PDF & Email

Genetic Testing best practices for Myotonic Dystrophy Patients

Because of the disease characteristics in DM1 and DM2, appropriate molecular testing and reporting is very important for the optimal counseling in myotonic dystrophy. Here, we describe best practice guidelinesfor clinical molecular genetic analysis and reporting in DM1 and DM2, including presymptomatic and prenatal testing.

Print Friendly, PDF & Email